Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 7:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,858 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo IV infusion Clear all
Terminated Phase 2 Interventional Results available

A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease

NCT04978493
View directory record Official record
Conditions
Crohn Disease
Interventions
BI 706321, Ustekinumab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
15
States / cities
Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose Exploration Intramuscular/Intravenous Prophylaxis Pharmacokinetic Exposure Response Study

NCT05872958
View directory record Official record
Conditions
COVID-19
Interventions
AZD3152, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Anniston, Alabama • Cullman, Alabama • Scottsdale, Arizona + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2025 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 1 Interventional

Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease

NCT02600130
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Longeveron Mesenchymal Stem Cells, Placebo
Biological
Lead sponsor
Longeveron Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Delray Beach, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

Evaluate the Neurological Effects of EryDex on Subjects With A-T

NCT06193200
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Dexamethasone sodium phosphate, Placebo
Drug · Other
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Baltimore, Maryland • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Results available

Safety and Pharmacokinetics of MK-2060 in Older Participants With End-Stage Renal Disease on Hemodialysis (MK-2060-004)

NCT03873038
View directory record Official record
Conditions
Renal Dialysis, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
3
States / cities
Orlando, Florida • Saint Paul, Minnesota • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer

NCT01186991
View directory record Official record
Conditions
Breast Cancer
Interventions
Onartuzumab, Bevacizumab, Paclitaxel, Bevacizumab Placebo, Onartuzumab Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
23
States / cities
Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2017 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

Intravenous Sub-dissociative Dose Ketamine Injection Versus Infusion for Analgesia in the Emergency Department

NCT02916927
View directory record Official record
Conditions
Pain
Interventions
Ketamine IV Infusion, Ketamine IV push
Drug
Lead sponsor
Alameda Health System
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2020 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

NCT01895361
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
SelG1, Placebo
Drug
Lead sponsor
Reprixys Pharmaceutical Corporation
Industry
Eligibility
16 Years to 65 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
49
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2020 · Synced Oct 11, 2026, 7:14 AM EDT
Terminated No phase listed Observational

An Evaluation of Patient Reported Outcomes and Clinical Outcomes

NCT06092970
View directory record Official record
Conditions
Post-Operative Complications in Cardiac Surgery
Interventions
RBT-1, Placebo
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
29
States / cities
Huntsville, Alabama • San Francisco, California • Stanford, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of RNS60 Given by IV to Healthy Subjects

NCT01264783
View directory record Official record
Conditions
Myocardial Infarct
Interventions
RNS60, Placebo
Drug
Lead sponsor
Revalesio Corporation
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 4, 2011 · Synced Oct 11, 2026, 7:14 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

NCT06284954
View directory record Official record
Conditions
Dermatomyositis, Myositis
Interventions
Empasiprubart IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
9
States / cities
Oceanside, California • DeBary, Florida • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2025 · Synced Oct 11, 2026, 7:14 AM EDT
Not listed Not applicable Interventional

Neurocognitive Functioning Following The PROMETA® Treatment Protocol In Subjects With Alcohol Dependence

NCT00570388
View directory record Official record
Conditions
Alcohol Dependence
Interventions
Prometa Treatment Program
Drug
Lead sponsor
Institute of Addiction Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2008 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Not applicable Interventional

Acute Renal Failure Post Liver Transplantation

NCT01907061
View directory record Official record
Conditions
Acute Renal Failure
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 71 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2020 · Synced Oct 11, 2026, 7:14 AM EDT
Recruiting Phase 3 Interventional

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
71
States / cities
Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 3 Interventional Results available

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

NCT03898180
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Pembrolizumab, Lenvatinib, Placebo for lenvatinib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
21
States / cities
Gilbert, Arizona • Clovis, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Free Fatty Acids-Induced Hypertension in Obese Subjects (Aim #2)

NCT02406586
View directory record Official record
Conditions
Hypertension, Diabetes
Interventions
Salsalate, Carvedilol, Placebo, Intralipid 20%
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy of Bimagrumab in Overweight and Obese Patients With Type 2 Diabetes

NCT03005288
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
BYM338 10 mg/kg, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Anaheim, California • Miami, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 11, 2026, 7:14 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001

NCT01760005
View directory record Official record
Conditions
Alzheimers Disease, Dementia, Alzheimers Disease, Familial
Interventions
Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), E2814, Lecanemab, Matching Placebo (E2814)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
490 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2028
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Minimizing ICU Neurological Dysfunction With Dexmedetomidine-induced Sleep

NCT02856594
View directory record Official record
Conditions
Postoperative Delirium, Sleep, Anesthesia
Interventions
Dexmedetomidine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years and older
Enrollment
469 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 11, 2026, 7:14 AM EDT
Active, not recruiting Phase 3 Interventional

Study of ALXN2220 Versus Placebo in Adults With ATTR-CM

NCT06183931
View directory record Official record
Conditions
Transthyretin Amyloid Cardiomyopathy
Interventions
ALXN2220, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
36
States / cities
Irvine, California • La Jolla, California • Palo Alto, California + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 11, 2026, 7:14 AM EDT
Terminated Phase 2 Interventional

An Assessment of an Attenuated Live Listeria Vaccine in CIN 2+

NCT01116245
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
ADXS11-001 (Lm-LLO-E7), Placebo Control
Biological · Drug
Lead sponsor
Advaxis, Inc.
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
15
States / cities
Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 4 Interventional Results available

Effect of DPP4 Inhibition on Vasoconstriction

NCT02639637
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sitagliptin, Placebo, Neuropeptide Y, Enalaprilat, Valsartan 160mg
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 27, 2018 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 2 Interventional Results available

Global Study of MK-2060 (Anti-Factor XI Monoclonal Antibody) in Participants With End Stage Renal Disease Receiving Hemodialysis (FXI Hemodialysis Study) (MK-2060-007)

NCT05027074
View directory record Official record
Conditions
End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Interventions
MK-2060, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
77
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 11, 2026, 7:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability of PRO 140 in HIV Uninfected Male Volunteers

NCT00110591
View directory record Official record
Conditions
HIV Infections
Interventions
PRO 140
Drug
Lead sponsor
CytoDyn, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2008
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced Oct 11, 2026, 7:14 AM EDT